Abstract:This study examines the role of new genome editing tools in treating retinitis pigmentosa (RP), particularly focusing on the Pde6a‐D670G mutation. Highlighting the potential of engineered base editing (BE) and prime editing (PE), it demonstrates how these advanced techniques can precisely correct the point mutation in Pde6a mouse model, effectively restoring retinal function. Retinitis pigmentosa (RP) is a complex spectrum of inherited retinal diseases marked by the gradual loss of photoreceptor cells, ultimately leading to blindness. Among these, mutations in PDE6A, responsible for encoding a cGMP‐specific phosphodiesterase, stand out as pivotal in autosomal recessive RP (RP43). Unfortunately, no effective therapy currently exists for this specific form of RP. However, recent advancements in genome editing, such as base editing (BE) and prime editing (PE), offer a promising avenue for precise and efficient gene therapy. Here, it is illustrated that the engineered BE and PE systems, particularly PE, exhibit high efficiency in rescuing a target point mutation with minimal bystander effects in an RP mouse model carrying the Pde6a (c.2009A > G, p.D670G) mutation. The optimized BE and PE systems are first screened in N2a cells and subsequently assessed in electroporated mouse retinas. Notably, the optimal PE system, delivered via dual adeno‐associated virus (AAV), precisely corrects the pathogenic mutation with average 9.4% efficiency, with no detectable bystander editing. This correction restores PDE6A protein expression, preserved photoreceptors, and rescued retinal function in Pde6a mice. Therefore, this study offers a proof‐of‐concept demonstration for the treatment of Pde6a‐related retinal degeneration using BE and PE systems.

Modeling a Cataract Disorder in Mice with Prime Editing.

CRISPR/Cas9 Targeting Events Cause Complex Deletions and Insertions at 17 Sites in the Mouse Genome

Improved Prime Editors Enable Pathogenic Allele Correction and Cancer Modelling in Adult Mice

Genetic Modification of Mice Using Prime Editing

Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

Development of a Highly Efficient Prime Editor System in Mice and Rabbits.

Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression

Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration

A prime editor mouse to model a broad spectrum of somatic mutations in vivo

Cost-effective Generation of A-to-G Mutant Mice by Zygote Electroporation of Adenine Base Editor Ribonucleoproteins.

Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing

Efficient prime editing in two-cell mouse embryos using PEmbryo

Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice

Efficient and multiplexed somatic genome editing with Cas12a mice

Correction of a Genetic Disease in Mouse Via Use of CRISPR-Cas9.

Precision Cancer Mouse Models Through Genome Editing with CRISPR-Cas9.

Effective Gene Editing by High-Fidelity Base Editor 2 in Mouse Zygotes

Deletion and replacement of long genomic sequences using prime editing

Efficient and Fast Generation of Relevant Disease Mouse Models by In Vitro and In Vivo Gene Editing of Zygotes

Large genomic fragment deletion and functional gene cassette knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos

High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics